Handelen Inovio Pharmaceuticals, Inc. - INO CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.06 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | 0.93 |
Open* | 0.93 |
1-Jaarlijkse Verandering* | -74.09% |
Dagelijks bereik* | 0.93 - 0.96 |
52 wekelijks bereik | 0.93-4.00 |
Weekgemiddelde volume (10 dagen) | 4.06M |
Gemiddeld volume (3 maanden) | 91.00M |
Marktkapitalisatie | 246.11M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 260.13M |
Omzet | 10.26M |
EPS | -1.19 |
Dividend (opbrengst %) | N/A |
Beta | 1.15 |
Volgende inkomsten datum | May 8, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 0.95 | 0.02 | 2.15% | 0.93 | 0.96 | 0.93 |
Mar 23, 2023 | 0.93 | -0.01 | -1.06% | 0.94 | 0.97 | 0.91 |
Mar 22, 2023 | 0.92 | -0.09 | -8.91% | 1.01 | 1.01 | 0.92 |
Mar 21, 2023 | 1.02 | -0.02 | -1.92% | 1.04 | 1.06 | 1.02 |
Mar 20, 2023 | 1.04 | -0.02 | -1.89% | 1.06 | 1.06 | 1.03 |
Mar 17, 2023 | 1.07 | -0.02 | -1.83% | 1.09 | 1.10 | 1.07 |
Mar 16, 2023 | 1.10 | -0.03 | -2.65% | 1.13 | 1.13 | 1.09 |
Mar 15, 2023 | 1.12 | 0.00 | 0.00% | 1.12 | 1.14 | 1.10 |
Mar 14, 2023 | 1.16 | -0.01 | -0.85% | 1.17 | 1.19 | 1.13 |
Mar 13, 2023 | 1.18 | 0.09 | 8.26% | 1.09 | 1.21 | 1.09 |
Mar 10, 2023 | 1.11 | 0.00 | 0.00% | 1.11 | 1.14 | 1.07 |
Mar 9, 2023 | 1.12 | -0.05 | -4.27% | 1.17 | 1.19 | 1.12 |
Mar 8, 2023 | 1.16 | 0.02 | 1.75% | 1.14 | 1.17 | 1.14 |
Mar 7, 2023 | 1.13 | -0.05 | -4.24% | 1.18 | 1.19 | 1.12 |
Mar 6, 2023 | 1.18 | -0.10 | -7.81% | 1.28 | 1.28 | 1.17 |
Mar 3, 2023 | 1.30 | 0.01 | 0.78% | 1.29 | 1.32 | 1.25 |
Mar 2, 2023 | 1.28 | 0.05 | 4.07% | 1.23 | 1.32 | 1.17 |
Mar 1, 2023 | 1.21 | -0.02 | -1.63% | 1.23 | 1.24 | 1.17 |
Feb 28, 2023 | 1.23 | -0.01 | -0.81% | 1.24 | 1.25 | 1.21 |
Feb 27, 2023 | 1.21 | -0.05 | -3.97% | 1.26 | 1.26 | 1.21 |
Inovio Pharmaceuticals, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale inkomsten | 1.77476 | 7.41122 | 4.11193 | 30.4819 | 42.2201 |
Inkomsten | 1.77476 | 7.41122 | 4.11193 | 30.4819 | 42.2201 |
Totale bedrijfskosten | 302.993 | 126.787 | 115.22 | 124.573 | 125.863 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 53.7523 | 37.2478 | 27.2032 | 29.3152 | 28.2904 |
Onderzoek & Ontwikkeling | 249.24 | 94.2454 | 88.0173 | 95.2579 | 98.5726 |
Ongebruikelijke uitgaven (inkomsten) | 0 | -4.70606 | 0 | 0 | -1 |
Bedrijfsresultaat | -301.218 | -119.376 | -111.109 | -94.0911 | -83.6429 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -2.34978 | -42.8094 | -10.1968 | -0.70688 | -4.56287 |
Netto inkomen voor belastingen | -303.224 | -162.89 | -120.809 | -94.798 | -88.2058 |
Netto inkomen na belastingen | -303.224 | -162.89 | -120.552 | -96.9678 | -88.2058 |
Minderheidsbelang | 0 | 1.06376 | 1.19256 | 0 | |
Netto inkomen voor extra. Posten | -303.659 | -166.411 | -119.359 | -96.9678 | -88.2058 |
Netto inkomen | -303.659 | -166.411 | -119.359 | -96.9678 | -88.2058 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -303.659 | -166.411 | -119.359 | -96.9678 | -88.2058 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -303.659 | -166.411 | -119.359 | -96.9678 | -88.2058 |
Verwaterd Netto Inkomen | -303.659 | -166.411 | -119.359 | -96.9678 | -88.2058 |
Verwaterd Gewogen Gemiddelde Aandelen | 208.83 | 155.127 | 98.718 | 92.54 | 81.7775 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -1.4541 | -1.07274 | -1.20909 | -1.04785 | -1.07861 |
Verwaterde Genormaliseerde Winst per Aandeel | -1.4541 | -1.10308 | -1.20909 | -1.04785 | -1.09084 |
Totale buitengewone posten | 0 | ||||
Overige, Netto | 0.34337 | -0.7049 | 0.4962 | ||
Equity In Affiliates | -0.43439 | -4.58461 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale inkomsten | 0.19907 | 0.83912 | 0.2917 | 0.27282 | 0.37112 |
Inkomsten | 0.19907 | 0.83912 | 0.2917 | 0.27282 | 0.37112 |
Totale bedrijfskosten | 71.9321 | 106.347 | 60.2449 | 83.4748 | 52.9256 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 15.9535 | 14.0486 | 13.1562 | 12.6663 | 13.8812 |
Onderzoek & Ontwikkeling | 55.9786 | 92.2988 | 47.0887 | 70.8084 | 39.0444 |
Bedrijfsresultaat | -71.733 | -105.508 | -59.9532 | -83.2019 | -52.5545 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -5.02205 | -1.61684 | -0.1874 | 0.87669 | -1.42223 |
Overige, Netto | -0.15347 | 0.1776 | -0.02849 | 0.18528 | 0.00898 |
Netto inkomen voor belastingen | -76.9085 | -106.948 | -60.169 | -82.14 | -53.9677 |
Netto inkomen na belastingen | -76.9085 | -106.948 | -60.169 | -82.14 | -53.9677 |
Minderheidsbelang | 0 | 0 | 0 | 0 | |
Equity In Affiliates | -2.16521 | 0 | 0 | 0 | -0.43439 |
Netto inkomen voor extra. Posten | -79.0737 | -106.948 | -60.169 | -82.14 | -54.4021 |
Netto inkomen | -79.0737 | -106.948 | -60.169 | -82.14 | -54.4021 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -79.0737 | -106.948 | -60.169 | -82.14 | -54.4021 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -79.0737 | -106.948 | -60.169 | -82.14 | -54.4021 |
Verwaterd Netto Inkomen | -79.0737 | -106.948 | -60.169 | -82.14 | -54.4021 |
Verwaterd Gewogen Gemiddelde Aandelen | 218.941 | 212.952 | 210.305 | 209.561 | 202.414 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.36117 | -0.50221 | -0.2861 | -0.39196 | -0.26877 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.36117 | -0.50221 | -0.2861 | -0.39196 | -0.26877 |
Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | 0 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totaal vlottende activa | 448.445 | 471.171 | 94.201 | 87.8148 | 138.362 |
Geldmiddelen en kortetermijnbeleggingen | 401.315 | 411.643 | 89.5341 | 81.2325 | 127.425 |
Geldmiddelen & Equivalenten | 71.1438 | 250.728 | 22.1961 | 23.6936 | 23.7866 |
Korte Termijn Investeringen | 330.171 | 160.915 | 67.338 | 57.5388 | 103.639 |
Totale Vorderingen, Netto | 8.03204 | 19.0637 | 2.03212 | 4.05494 | 6.48982 |
Accounts Receivable - Trade, Net | 5.46685 | 18.56 | 0.70007 | 3.31636 | 6.00321 |
Prepaid Expenses | 39.0982 | 40.4639 | 2.63474 | 2.5274 | 4.44691 |
Total Assets | 495.941 | 539.772 | 143.952 | 131.113 | 187.239 |
Property/Plant/Equipment, Total - Net | 29.0242 | 24.0894 | 26.556 | 15.949 | 18.3202 |
Property/Plant/Equipment, Total - Gross | 47.9686 | 40.083 | 39.7225 | 25.9489 | 25.4267 |
Accumulated Depreciation, Total | -18.9444 | -15.9936 | -13.1665 | -9.99992 | -7.10656 |
Goodwill, Net | 10.5134 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
Intangibles, Net | 2.62636 | 3.14677 | 3.69385 | 4.76015 | 6.00973 |
Long Term Investments | 3.9068 | 4.89475 | 6.31536 | 9.40591 | 11.3945 |
Other Long Term Assets, Total | 1.42579 | 25.9575 | 2.67202 | 2.67 | 2.63935 |
Total Current Liabilities | 65.7416 | 41.706 | 31.9893 | 35.2998 | 35.4054 |
Accounts Payable | 24.2137 | 0.82552 | 6.91908 | 10.0438 | 7.56483 |
Payable/Accrued | 0.54803 | 0.64297 | 0.72973 | 4.60189 | 8.64376 |
Accrued Expenses | 36.3611 | 32.658 | 17.4428 | 15.1386 | 16.609 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 4.61885 | 7.57944 | 6.89777 | 5.51547 | 2.58779 |
Total Liabilities | 96.2721 | 78.6317 | 140.516 | 44.1771 | 44.8467 |
Total Long Term Debt | 14.9597 | 18.6558 | 77.0229 | 0 | 0 |
Deferred Income Tax | 0.03205 | 0.03205 | 0.03205 | 0.02477 | 0.02477 |
Minority Interest | 0 | 1.96976 | 0.09627 | 0.09627 | |
Other Liabilities, Total | 15.5387 | 18.2379 | 29.5025 | 8.75633 | 9.32027 |
Total Equity | 399.669 | 461.141 | 3.4351 | 86.9361 | 142.393 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.21738 | 0.18685 | 0.10136 | 0.09723 | 0.09036 |
Additional Paid-In Capital | 1609.59 | 1367.41 | 742.647 | 707.794 | 665.776 |
Retained Earnings (Accumulated Deficit) | -1209.86 | -906.197 | -739.786 | -620.426 | -523.356 |
Other Equity, Total | -0.28224 | -0.25615 | 0.47261 | -0.52887 | -0.11701 |
Total Liabilities & Shareholders’ Equity | 495.941 | 539.772 | 143.952 | 131.113 | 187.239 |
Total Common Shares Outstanding | 217.383 | 186.851 | 101.361 | 97.2258 | 90.3576 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00002 | 0.00002 | 0.00002 |
Long Term Debt | 14.9597 | 18.6558 | 77.0229 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totaal vlottende activa | 399.907 | 448.445 | 487.397 | 542.425 | 588.435 |
Geldmiddelen en kortetermijnbeleggingen | 360.394 | 401.315 | 394.941 | 443.678 | 518.604 |
Geldmiddelen & Equivalenten | 59.0095 | 71.1438 | 67.9413 | 58.9253 | 83.6342 |
Korte Termijn Investeringen | 301.384 | 330.171 | 326.999 | 384.752 | 434.97 |
Totale Vorderingen, Netto | 7.4908 | 8.03204 | 7.12509 | 13.8513 | 10.2589 |
Accounts Receivable - Trade, Net | 4.00368 | 5.46685 | 4.77077 | 13.1283 | 9.91192 |
Prepaid Expenses | 32.0223 | 39.0982 | 85.3313 | 84.8957 | 59.5722 |
Total Assets | 445.511 | 495.941 | 535.763 | 591.842 | 654.863 |
Property/Plant/Equipment, Total - Net | 27.9484 | 29.0242 | 29.4573 | 30.2847 | 23.3933 |
Goodwill, Net | 10.5134 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
Intangibles, Net | 2.49959 | 2.62636 | 2.75313 | 2.8799 | 3.01 |
Long Term Investments | 3.36907 | 3.9068 | 3.88671 | 3.90871 | 3.62989 |
Other Long Term Assets, Total | 1.2738 | 1.42579 | 1.75508 | 1.83087 | 25.8819 |
Total Current Liabilities | 59.3597 | 65.7416 | 51.3758 | 51.749 | 41.5395 |
Payable/Accrued | 39.5228 | 48.1926 | 29.1465 | 31.8694 | 26.7428 |
Accrued Expenses | 14.5007 | 12.9302 | 16.1552 | 12.88 | 9.7668 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 5.33615 | 4.61885 | 6.07406 | 6.99953 | 5.02986 |
Total Liabilities | 90.4261 | 96.2721 | 82.1901 | 83.2884 | 73.2572 |
Total Long Term Debt | 16.2079 | 14.9597 | 14.4793 | 14.5365 | 14.0697 |
Long Term Debt | 16.2079 | 14.9597 | 14.4793 | 14.5365 | 14.0697 |
Deferred Income Tax | 0.03205 | 0.03205 | 0.03205 | 0.03205 | 0.03205 |
Other Liabilities, Total | 14.8265 | 15.5387 | 16.303 | 16.9709 | 17.616 |
Total Equity | 355.085 | 399.669 | 453.572 | 508.554 | 581.606 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.22651 | 0.21738 | 0.21036 | 0.21015 | 0.20933 |
Additional Paid-In Capital | 1642.42 | 1609.59 | 1556.53 | 1551.35 | 1542.26 |
Retained Earnings (Accumulated Deficit) | -1287.1 | -1209.86 | -1102.91 | -1042.74 | -960.599 |
Other Equity, Total | -0.45789 | -0.28224 | -0.25793 | -0.26591 | -0.26571 |
Total Liabilities & Shareholders’ Equity | 445.511 | 495.941 | 535.763 | 591.842 | 654.863 |
Total Common Shares Outstanding | 226.511 | 217.383 | 210.363 | 210.147 | 209.334 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -303.659 | -167.475 | -120.552 | -96.9678 | -88.2058 |
Geldmiddelen uit Operationele Activiteiten | -215.709 | -177.979 | -97.8501 | -73.5502 | -63.2089 |
Geldmiddelen uit Operationele Activiteiten | 3.0401 | 3.039 | 3.59839 | 3.74718 | 1.85038 |
Amortization | 0.52042 | 0.54708 | 1.06629 | 1.24958 | 1.61867 |
Deferred Taxes | 0 | 0 | 0.0054 | 0 | -0.15003 |
Niet-Geldelijke Posten | 34.0382 | 56.9816 | 21.5747 | 13.3131 | 22.391 |
Veranderingen in het Operationeel Kapitaal | 50.3515 | -71.0718 | -3.54312 | 5.10778 | -0.71312 |
Geldmiddelen uit Investeringsactiviteiten | -175.344 | -58.7957 | -9.045 | 42.4199 | -27.8311 |
Kapitaaluitgaven | -1.23101 | -1.52067 | -0.98793 | -2.08502 | -10.2939 |
Overige Cash Flow investeringsposten, Totaal | -174.113 | -57.2751 | -8.05707 | 44.5049 | -17.5372 |
Geldmiddelen uit Financieringsactiviteiten | 211.499 | 465.28 | 105.398 | 31.0373 | 95.6902 |
Financiering van Cash Flow Posten | 0 | 2.37997 | -0.35463 | 0 | 0 |
Uitgifte (Aflossing) van aandelen, netto | 211.499 | 462.728 | 8.3086 | 31.0373 | 95.6902 |
Wisselkoerseffecten | -0.03013 | 0.02721 | |||
Nettowijziging in Geldmiddelen | -179.584 | 228.532 | -1.49754 | -0.09295 | 4.65011 |
Contant Betaalde Rente | 1.0778 | 4.62476 | 2.71759 | ||
Uitgifte (Aflossing) van Schulden, Netto | 0 | 0.17162 | 97.4436 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -79.0737 | -303.659 | -196.711 | -136.542 | -54.4021 |
Cash From Operating Activities | -61.8821 | -215.709 | -177.817 | -131.327 | -52.8674 |
Cash From Operating Activities | 0.92938 | 3.0401 | 2.0949 | 1.3616 | 0.6607 |
Amortization | 0.12677 | 0.52042 | 0.39364 | 0.26687 | 0.13677 |
Non-Cash Items | 15.7913 | 34.0382 | 25.1351 | 17.613 | 11.789 |
Cash Interest Paid | 0.53349 | 1.0778 | 1.0778 | 0.54432 | 0.54432 |
Changes in Working Capital | 0.3442 | 50.3515 | -8.72991 | -14.026 | -11.0518 |
Cash From Investing Activities | 21.3323 | -175.344 | -168.85 | -224.809 | -275.115 |
Capital Expenditures | 0 | -1.23101 | -0.58735 | -0.41873 | -0.21082 |
Other Investing Cash Flow Items, Total | 21.3323 | -174.113 | -168.263 | -224.39 | -274.905 |
Cash From Financing Activities | 28.422 | 211.499 | 163.904 | 164.345 | 160.903 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 28.422 | 211.499 | 163.904 | 164.345 | 160.903 |
Foreign Exchange Effects | -0.00656 | -0.03013 | -0.02281 | -0.01194 | -0.01442 |
Net Change in Cash | -12.1343 | -179.584 | -182.787 | -191.803 | -167.094 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Deferred Taxes | 0 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 12.0986 | 31472352 | 5446385 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.6927 | 20011271 | 1633565 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.5398 | 17012107 | 1660191 | 2022-12-31 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 3.2563 | 8470700 | 919851 | 2022-12-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8799 | 4890119 | 290102 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.6593 | 4316357 | 2218122 | 2022-12-31 | HIGH |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.1982 | 3116926 | -22713 | 2022-12-31 | LOW |
Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 1.1391 | 2963112 | 599923 | 2022-12-31 | MED |
Renaissance Technologies LLC | Hedge Fund | 0.9889 | 2572500 | 248800 | 2022-12-31 | HIGH |
BofA Global Research (US) | Research Firm | 0.9497 | 2470457 | 790074 | 2022-12-31 | LOW |
Kim (Jong Joseph Ph.D.) | Individual Investor | 0.9018 | 2346000 | 145247 | 2022-03-17 | LOW |
Nuveen LLC | Pension Fund | 0.7915 | 2058828 | 884345 | 2022-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.786 | 2044756 | 120747 | 2022-12-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.7191 | 1870601 | 52686 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.6752 | 1756282 | -2403512 | 2022-12-31 | HIGH |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.6197 | 1612084 | -30372 | 2022-12-31 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.5868 | 1526475 | -578158 | 2022-12-31 | MED |
Barclays Bank PLC | Investment Advisor | 0.5204 | 1353614 | 197133 | 2022-12-31 | MED |
Citi Investment Research (US) | Research Firm | 0.4536 | 1180030 | -834269 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.4025 | 1047154 | -89572 | 2022-12-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Inovio Pharmaceuticals Company profile
Over Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (INOVIO) is een biotechnologiebedrijf. Het bedrijf richt zich op het op de markt brengen van ontworpen desoxyribonucleïnezuur (DNA) geneesmiddelen en vaccins om mensen te helpen beschermen tegen infectieziekten, waaronder COVID-19, en om mensen te helpen bij de behandeling van kanker en aandoeningen die verband houden met het humaan papillomavirus (HPV). De pijplijn met DNA-geneesmiddelen bestaat uit drie soorten productkandidaten, namelijk profylactische DNA-vaccins, therapeutische DNA-immunotherapieën en DNA-gecodeerde monoklonale en bispecifieke antilichamen (dMAbs en dBTA's), die gebruik maken van de twee componenten van INOVIO's geïntegreerde platform, SynCon en CELLECTRA. De SynCon-technologie van het bedrijf creëert geoptimaliseerde plasmiden. INOVIO's CELLECTRA smart delivery devices vergemakkelijken de opname van haar DNA-geneesmiddelen in de cel. Haar SynCon DNA-geneesmiddelen zijn ontworpen om antigeenspecifieke antilichaam- en T-celresponsen op te wekken.
Industry: | Biotechnology & Medical Research (NEC) |
6769 Mesa Ridge Rd.
SAN DIEGO
CALIFORNIA 92121
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen